Request Trial
shutterstock_1463056853_poptika
Poptika / Shutterstock.com
22 June 2021BiotechLinda Thayer, Aaron Capron and Sneha Nyshadham

Navigating patent eligibility in digital healthcare

Digital healthcare technologies are transforming the healthcare industry and quickly changing the way healthcare is delivered. Disruptive technologies such as artificial intelligence, together with faster processing devices, have made it possible to analyse and predict risk and outcomes, sometimes in real time.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Regeneron and Amgen call a truce on two Eylea biosimilar patents
28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
Biotech
10x and Parse set to end sequencing feud after appeals court defeat
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
Biotech
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

Regulatory and patent teams must align, say Amgen, Genentech, ORIC
EPO starts using AI for minutes but no access to transcripts for parties
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
In-house counsel rethink patent filing strategies as costs mount
Fenwick hires NY partner to advise on regulatory matters
Oura targets Ultrahuman’s redesigned smart ring following import ban
Weil collapse leaves IP talent facing uncertain future after major expansion